Editorial
Copyright ©The Author(s) 2016.
World J Gastroenterol. Nov 28, 2016; 22(44): 9661-9673
Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9661
Table 1 Summary of studies concerning radiofrequency ablation
AuthorsNumber of patientsLesion typeLocationTreatment typeApproachNeedleMean treatment durationConclusion
D’Onofrio et al[8]18Pancreatic ductal adenocarcinomaHeadRadiofrequency ablationPercutaneous with US17 G3 min and 13 sHigh success rate, with 40% of cases showing CA 19.9 reduction
Carrafiello et al[26]1Pancreatic metastases from renal cellBody-tailRadiofrequency ablationPercutaneous with CT19 G8 min and 35 sRFA is feasible for
metastatic lesions at body-tail
Limmer et al[27]1InsulinomaBody-tailRadiofrequency ablationPercutaneous with CT16 G18 minRFA proved to be a clinically successful
procedure
Wu et al[28]1GastrinomaTailRadiofrequency ablationPercutaneous transplenic with CT--Percutaneous transplenic RFA is feasible
Singh et al[29]11Pancreatic ductal adenocarcinoma-Radiofrequency ablation1 percutaneous with CT + 10 laparoscopic--RFA is a safe and feasible technique of tumor cytoreduction
Rossi et al[30]8Pancreatic neuroendocrine tumorsHead and body-tailRadiofrequency ablationPercutaneous with CT17 and 19 G9 minRFA is a feasible, safe, and effective option